停用β受体阻滞剂对射血分数保留心衰患者功能能力的影响
PRESERVE-HR多中心随机交叉试验纳入稳定HFpEF、NYHA II-III级、既往使用β受体阻滞剂且伴变时性功能不全的患者,比较停药与继续用药两个2周阶段。停药后峰值摄氧量及峰值摄氧量占预计值百分比均显著升高,提示此类患者停用β受体阻滞剂可改善最大功能能力。
要点
- 伴变时性功能不全的HFpEF患者停用β受体阻滞剂后峰值摄氧量显著提高。
- 停药后峰值摄氧量占预计值百分比亦显著提高。
- HFpEF患者使用β受体阻滞剂值得重新评估。
核心结论
- 在HFpEF合并变时性功能不全患者中,停用β受体阻滞剂改善了最大功能能力。
- 作者认为HFpEF中使用β受体阻滞剂值得深入重新评估。
研究设计与样本
- 多中心、随机、研究者盲法、交叉临床试验,两个2周治疗期之间设2周洗脱期。
- 患者先随机分为停药组(A组,n=26)与继续用药组(B组,n=26),随后交叉接受相反干预。
- 纳入稳定HFpEF、NYHA II-III级、既往接受β受体阻滞剂治疗且伴变时性功能不全的患者。
- 主要结局为试验结束时测得的峰值摄氧量(peak Vo2)及峰值摄氧量占预计值百分比(peak Vo2%)变化。
- 采用线性混合回归分析处理交叉试验的配对数据特征。
主要发现
- 平均年龄72.6 ± 13.1岁,女性占59.6%,NYHA II级占66.7%。
- 基线平均峰值摄氧量为12.4 ± 2.9 mL/kg/min,峰值摄氧量占预计值百分比为72.4 ± 17.8%。
- 各治疗组间基线无显著差异。
- 停用β受体阻滞剂后峰值摄氧量显著升高(14.3 vs 12.2 mL/kg/min,Δ +2.1 mL/kg/min;P < 0.001)。
- 停用β受体阻滞剂后峰值摄氧量占预计值百分比显著升高(81.1 vs 69.4%,Δ +11.7%;P < 0.001)。
关键数值与推荐
- 主要结局为峰值摄氧量及峰值摄氧量占预计值百分比。
- 停药后峰值摄氧量14.3 vs 12.2 mL/kg/min(Δ +2.1 mL/kg/min),P < 0.001。
- 停药后峰值摄氧量占预计值百分比81.1 vs 69.4%(Δ +11.7%),P < 0.001。
临床怎么用
- 对HFpEF合并变时性功能不全且正在使用β受体阻滞剂的患者,可考虑评估停药对运动耐量的影响。
- β受体阻滞剂在HFpEF中的常规使用需结合变时性功能状态重新审视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet β-blockers are commonly used in HFpEF despite the lack of robust evidence. OBJECTIVES: This study aimed to evaluate the effect of β-blocker withdrawal on peak oxygen consumption (peak Vo2) in patients with HFpEF and chronotropic incompetence. METHODS: This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with β-blockers, and chronotropic incompetence were first randomized to withdrawing from (arm A: n = 26) versus continuing (arm B: n = 26) β-blocker treatment and were then crossed over to receive the opposite intervention. Changes in peak Vo2 and percentage of predicted peak Vo2 (peak Vo2%) measured at the end of the trial were the primary outcome measures. To account for the paired-data nature of this crossover trial, linear mixed regression analysis was used. RESULTS: The mean age was 72.6 ± 13.1 years, and most of the patients were women (59.6%) in New York Heart Association functional class II (66.7%). The mean peakVo2 and peak Vo2% were 12.4 ± 2.9 mL/kg/min, and 72.4 ± 17.8%, respectively. No significant baseline differences were found across treatment arms. Peak Vo2 and peak Vo2% increased significantly after β-blocker withdrawal (14.3 vs 12.2 mL/kg/min [Δ +2.1 mL/kg/min]; P < 0.001 and 81.1 vs 69.4% [Δ +11.7%]; P < 0.001, respectively). CONCLUSIONS: β-blocker withdrawal improved maximal functional capacity in patients with HFpEF and chronotropic incompetence. β-blocker use in HFpEF deserves profound re-evaluation. (β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity [PRESERVE-HR]; NCT03871803; 2017-005077-39).
引用
- Palau, Seller, Domínguez, et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2021. PMID: 34794685. doi:10.1016/j.jacc.2021.08.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。